Compile Data Set for Download or QSAR
maximum 50k data
Found 21 with Last Name = 'fensholdt' and Initial = 'j'
TargetCytochrome P450 2D6(Homo sapiens (Human))
Leo Pharma

US Patent
LigandPNGBDBM50416875(AMG-073 | AMG073 HCL | CINACALCET | CINACALCET HYD...)
Affinity DataIC50:  50nMpH: 7.4 T: 2°CAssay Description:Incubations were conducted in 96 well microtiter plates based on a method described by BD Biosciences. To the first well in each row, a NADPH regener...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Leo Pharma

Curated by ChEMBL
LigandPNGBDBM4851((4-chlorophenyl)-[4-(4-pyridylmethyl)phthalazin-1-...)
Affinity DataIC50:  63nMAssay Description:In vitro inhibition of KDRMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Leo Pharma

Curated by ChEMBL
LigandPNGBDBM17028((3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-...)
Affinity DataIC50:  100nMAssay Description:In vitro inhibition of KDRMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Leo Pharma

Curated by ChEMBL
LigandPNGBDBM17015((3Z)-3-(1H-pyrrol-2-ylmethylidene)-2,3-dihydro-1H-...)
Affinity DataIC50:  140nMAssay Description:In vitro inhibition of KDRMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Leo Pharma

Curated by ChEMBL
LigandPNGBDBM4810((3Z)-3-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-...)
Affinity DataIC50:  230nMAssay Description:In vitro inhibition of KDRMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Leo Pharma

Curated by ChEMBL
LigandPNGBDBM50171851(3-[1-(4-Bromo-3,5-dimethyl-1H-pyrrol-2-yl)-meth-(Z...)
Affinity DataIC50:  320nMAssay Description:In vitro inhibition of KDRMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Leo Pharma

Curated by ChEMBL
LigandPNGBDBM50171852(3-[1-(5-Hydroxymethyl-3-methyl-1H-pyrrol-2-yl)-met...)
Affinity DataIC50:  320nMAssay Description:In vitro inhibition of KDRMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Leo Pharma

Curated by ChEMBL
LigandPNGBDBM50171858(Acetic acid 3-[1-(3,5-dimethyl-1H-pyrrol-2-yl)-met...)
Affinity DataIC50:  400nMAssay Description:In vitro inhibition of KDRMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Leo Pharma

Curated by ChEMBL
LigandPNGBDBM50171856(3-[1-(3,5-Dimethyl-1H-pyrrol-2-yl)-meth-(Z)-yliden...)
Affinity DataIC50:  500nMAssay Description:In vitro inhibition of KDRMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Leo Pharma

Curated by ChEMBL
LigandPNGBDBM50171857(3-[1-(4-Chloro-3,5-dimethyl-1H-pyrrol-2-yl)-meth-(...)
Affinity DataIC50:  1.00E+3nMAssay Description:In vitro inhibition of KDRMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Leo Pharma

Curated by ChEMBL
LigandPNGBDBM50171850(4-Methyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylideneme...)
Affinity DataIC50:  8.00E+3nMAssay Description:In vitro inhibition of KDRMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2D6(Homo sapiens (Human))
Leo Pharma

US Patent
LigandPNGBDBM253032(US9487494, 53 (Compound 1056))
Affinity DataIC50:  1.00E+4nMpH: 7.4 T: 2°CAssay Description:Incubations were conducted in 96 well microtiter plates based on a method described by BD Biosciences. To the first well in each row, a NADPH regener...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 2D6(Homo sapiens (Human))
Leo Pharma

US Patent
LigandPNGBDBM253030(US9487494, 127 (Compound 1136))
Affinity DataIC50:  1.00E+4nMpH: 7.4 T: 2°CAssay Description:Incubations were conducted in 96 well microtiter plates based on a method described by BD Biosciences. To the first well in each row, a NADPH regener...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Leo Pharma

Curated by ChEMBL
LigandPNGBDBM50171859(4-Methyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylideneme...)
Affinity DataIC50: >1.00E+4nMAssay Description:In vitro inhibition of KDRMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetVascular endothelial growth factor receptor 2(Homo sapiens (Human))
Leo Pharma

Curated by ChEMBL
LigandPNGBDBM50171854(4-Methyl-5-[2-oxo-1,2-dihydro-indol-(3Z)-ylideneme...)
Affinity DataIC50: >1.00E+4nMAssay Description:In vitro inhibition of KDRMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2D6(Homo sapiens (Human))
Leo Pharma

US Patent
LigandPNGBDBM253031(US9487494, 106 (Compound 1115))
Affinity DataIC50:  1.30E+4nMpH: 7.4 T: 2°CAssay Description:Incubations were conducted in 96 well microtiter plates based on a method described by BD Biosciences. To the first well in each row, a NADPH regener...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 2D6(Homo sapiens (Human))
Leo Pharma

US Patent
LigandPNGBDBM253028(US9487494, 137 (Compound 1146))
Affinity DataIC50:  1.60E+4nMpH: 7.4 T: 2°CAssay Description:Incubations were conducted in 96 well microtiter plates based on a method described by BD Biosciences. To the first well in each row, a NADPH regener...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 2D6(Homo sapiens (Human))
Leo Pharma

US Patent
LigandPNGBDBM253029(US9487494, 133 (Compound 1142))
Affinity DataIC50:  2.50E+4nMpH: 7.4 T: 2°CAssay Description:Incubations were conducted in 96 well microtiter plates based on a method described by BD Biosciences. To the first well in each row, a NADPH regener...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 2D6(Homo sapiens (Human))
Leo Pharma

US Patent
LigandPNGBDBM253025(US9487494, 171 (Compound 1186))
Affinity DataIC50:  5.00E+4nMpH: 7.4 T: 2°CAssay Description:Incubations were conducted in 96 well microtiter plates based on a method described by BD Biosciences. To the first well in each row, a NADPH regener...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 2D6(Homo sapiens (Human))
Leo Pharma

US Patent
LigandPNGBDBM253026(US9487494, 175 (Compound 1190))
Affinity DataIC50:  7.90E+4nMpH: 7.4 T: 2°CAssay Description:Incubations were conducted in 96 well microtiter plates based on a method described by BD Biosciences. To the first well in each row, a NADPH regener...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 2D6(Homo sapiens (Human))
Leo Pharma

US Patent
LigandPNGBDBM253027(US9487494, 299 (Compound 1338))
Affinity DataIC50:  1.00E+5nMpH: 7.4 T: 2°CAssay Description:Incubations were conducted in 96 well microtiter plates based on a method described by BD Biosciences. To the first well in each row, a NADPH regener...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent